PENTOXIFYLLINE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Non-selective phosphodiesterase inhibitor; increases intracellular cAMP, leading to decreased blood viscosity, increased erythrocyte deformability, and reduced platelet aggregation.

What the body does with it

Metabolism	Hepatic (major) via CYP1A2 and CYP3A4; some metabolism via CYP2E1 and CYP2C8. Active metabolites.
Excretion	Renal: 95% as metabolites (primarily 1-(5-hydroxyhexyl)-3,7-dimethylxanthine and 1-(3-carboxypropyl)-3,7-dimethylxanthine) and <4% as unchanged drug; biliary/fecal: minimal.
Half-life	Terminal half-life: 0.4–0.8 hours (pentoxifylline) and 1.0–1.6 hours (active metabolites); clinical context: short half-life necessitates frequent dosing (e.g., 400 mg three times daily) for sustained hemorheologic effects.
Protein binding	Pentoxifylline: 80–85% bound to albumin; metabolites: also highly protein-bound.
Volume of Distribution	Vd: 3–5 L/kg indicating extensive tissue distribution, including erythrocytes and vascular endothelium.
Bioavailability	Oral: 20–30% (extensive first-pass metabolism); intravenous: 100%.
Onset of Action	Oral: 2–4 weeks for clinical improvement in intermittent claudication; intravenous: immediate hemorheologic effects (within minutes).
Duration of Action	Oral: duration of hemorheologic effects persists for several hours after dosing; clinical improvement requires chronic therapy (weeks).

Classification & Brands

Dosing & administration

400 mg orally three times daily with meals.

Dosage form	TABLET, EXTENDED RELEASE
Renal impairment	No dose adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, reduce dose by 30-50%.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 30-50%; Child-Pugh Class C: avoid use.
Pediatric use	Not approved for pediatric use; safety and efficacy not established.
Geriatric use	Start at 400 mg once daily, titrate slowly to 400 mg twice daily; monitor for hypotension and arrhythmias.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Antihypertensive drugs may have additive effects Can cause nausea and dizziness.

Breastfeeding

Pentoxifylline is excreted into human breast milk in small amounts; the milk-to-plasma ratio (M/P) is approximately 0.5. Based on limited data, the estimated daily infant dose is <1% of maternal weight-adjusted dose. Caution is advised in breastfeeding mothers due to potential for CNS stimulation in infants. Monitor infant for irritability or sleep disturbances.

Teratogenic Risk

Pentoxifylline is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and increased resorptions at high doses, but no teratogenic effects were observed. There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if potential benefit justifies potential risk to fetus. Second and third trimesters: Limited data suggest no increased risk of major malformations, but consider potential for adverse effects on uterine blood flow.

Warnings & precautions

■ FDA Black Box Warning

None approved by FDA.

Side Effect Profile

Common Effects	Nausea
Serious Effects

Absolute Contraindications

Hypersensitivity to pentoxifylline or other methylxanthines; recent or active hemorrhage (e.g., retinal, cerebral); concurrent use with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) may increase toxicity.

Clinical Precautions

Precautions

Risk of gastrointestinal bleeding, especially with concomitant anticoagulants; avoid in patients with recent hemorrhage; use with caution in renal impairment (creatinine clearance <30 mL/min) and hepatic impairment; potential for hypotension; caution in elderly.

Clinical Tips & Counseling

Drug interactions

Loading safety data…